Abstract
Introduction
Tuberculosis (TB) is a major worldwide public health issue and the emergence of drugresistant strains poses a great concern for the control of this disease. Multidrug-resistant tuberculosis (MDR-TB) is defined by resistance to at least rifampicin (RIF) and isoniazid (INH). These strains are spreading worldwide and can acquire additional resistance to fluoroquinolones and one of the three injectable drugs: capreomycin, kanamycin or amikacin becoming extensively drug-resistant (XDR-TB). Difficulties in MDR-TB detection contribute to the dissemination of these strains, since conventional drug susceptibility testing is timeconsuming, costly and poses technical challenges. New molecular biology techniques allow for rapid diagnosis and could represent a solution to those problems, improving the management of MDR-TB cases. According to World Health Organization Global TB report 2015, MDR-TB accounted for 3.3% of new TB cases and 20% of previously treated cases worldwide. In 2014 there were 300,000 estimated MDR-TB cases among notified pulmonary cases but only 41% of them were detected (123,000) (WORLD HEALTH ORGANIZATION [1]). In Romania, the TB incidence and prevalence rates were estimated at 81 per 100,000 populations (71-91%000) and 99 per 100,000 populations (41-184%000), respectively. These were the highest values for TB incidence and prevalence rates in the European Union/European Economic Area countries in 2014 (ECDC/WHO REGIONAL OFFICE FOR EUROPE [2] ). In our country, MDR-TB represented 2.8% of notified new TB cases and 11% of notified previously treated TB cases. The number of estimated MDR-TB cases among notified pulmonary TB cases was 650 and 578 of them (89%) were confirmed (WORLD HEALTH ORGANIZATION [1]). In this situation, the revision of diagnosis algorithm in order to improve the cost-benefit ratio and to support patients' treatment, especially for MDR-TB cases, becomes a crucial objective. Our objective was to evaluate the opportunity of using molecular techniques for rapid detection of MDR-TB strains in routine diagnosis. To reach this objective, we have analyzed the performance parameters of MAS-PCR technique (sensitivity, specificity, accuracy) for detection of RIF and INH resistance and identification of MDR strains, in comparison to conventional phenotypic drug susceptibility testing. We have also calculated the cost of genetic testing/strain.
Materials and Methods

Selected strains
The study included a collection of 83 non-duplicate Mycobacterium tuberculosis strains from the Bacteriology Laboratory of the Clinical Hospital of Pulmonology Iasi, isolated from patients with pulmonary TB between January 2008 and December 2012.
Drug susceptibility testing (DST)
We used conventional phenotypic testing (proportion method) on Löwenstein-Jensen medium for antibiotic susceptibility to first line antituberculous drugs (G. CANETTI & al. [3] ; G. CANETTI & al. [4] ; S.J. KIM [5] ). Reference strain M. tuberculosis H37Rv ATCC 27294 was used as control. DNA extraction procedure DNA extraction was done using a method previously described (C. CAVASOGLU & al. [6] ) and modified: a 2 McFarland culture suspension of M. tuberculosis was inactivated by boiling for 20 min, followed by sonication for 15 min and centrifugation for 5 min at 14000 rpm. DNA yield in the supernatant was determined by spectrophotometry using NanoPhotometer® P 300 (Implen GmbH, Germany).
MAS-PCR
For the molecular detection of RIF and INH resistance we have applied a single-step multiplex allele-specific PCR, which allowed the simultaneous detection of mutations in codons 531, 526 and 516 of rpoB gene and in codon 315 of katG gene, as well as in promoter region mabA-inhA:-15. We used the Corbett Palm-Cycler (Qiagen, SUA) and primers synthesized by Eurogentec (Eurogentec S.A., Liège, Belgium) ( Table 1) . [9] ) and modified: initial denaturation 3 min at 96ºC, followed by 23 cycles as follows: 50 s at 95ºC, 40 s at 63ºC and 1 min at 72ºC, with a final extension of 7 min at 72ºC. Reference strain M. tuberculosis H37Rv ATCC 27294 represented the control for amplification. Each reaction was performed in triplicate. Analysis of amplification products was done by electrophoresis in 2.5% agarose gel. The absence of amplification signified mutation in analyzed codon.
The cost of genotypic testing / strain
We have calculated the cost of testing/strain depending on the acquisition price of reagents for MAS-PCR (primers, master mix, nuclease-free water) and electrophoresis (agarose, buffer solution, ethidium bromide). All prices included VAT 20%. The cost did not include the expenses for infrastructure, equipment, consumables and staff (training and salaries).
Statistical analysis
Statistical analysis was performed using Epi Info TM . A p-value of less than 0.05 was considered significant.
Results and discussion
In our study, the phenotypic testing of resistance to first line antituberculous drugs showed that, of the total 83 strains, 80 were MDR (96.38%), one strain had monoresistance to RIF (1.2%), and one to INH (1.2%), while one strain was sensitive to first line antituberculous drugs (1.2%). The rates of resistance to first line antituberculous drugs are summarized in Figure 1 . MAS-PCR technique detected RIF resistance in 72 strains, with a sensitivity of 88.88% (81-95%, a 95% confidence interval, p=0.0002). The specificity of MAS-PCR in detecting RIF resistance was 100%, the positive predictive value was 100%, and the test accuracy was 89.15% ( Of the 80 MDR-TB strains, MAS-PCR technique identified 71 strains, with a sensitivity of 88.75% (80-95%, a 95% confidence interval, p=0.00001). Positive predictive value was 100%, and test accuracy was 89.15% (Table 4) . [13] ). Other studies conducted in Eastern European countries reported frequencies of mutations that induced resistance to INH and RIF similar to our findings (Figure 2 ). These results demonstrate that using MAS-PCR technique for highlighting five key mutations that induce resistance to INH and RIF provides good sensitivity in detection of MDR-TB strains.
We have evaluated the cost of MAS-PCR assay at about US$ 1.62/strain (Table 5 ). In a study conducted by Tho et al. , the cost of MAS-PCR for detection of RIF resistance was about US$ 1.60 per sample (excluding salary and equipment costs) (D.Q. THO & al. [20] ). In another study, Imperiale and collaborators estimated a cost of MAS-PCR of US$ 14 including staff, overheads and medical supplies (B.R. IMPERIALE & al. [21] ). Our technique had a lower cost than the commercial molecular kits for MDR-TB diagnosis whose costs were estimated between US$ 50 (D.Q. THO & al. [20] ) and US$ 94 per strip (B.R. IMPERIALE & al. [21] ) and also lower than the automated culture methods whose costs were approximately US$ 10 (S. SOLOMON & al. [22] ) to US$ 31 (B.R. IMPERIALE & al. [21] ). In comparison to microscopic observation drug susceptibility assay (US$ 2) (S. SOLOMON & al. [22] ) and DST on Löwenstein-Jensen medium (US$ 16) (B.R. IMPERIALE & al. [21] ), MAS-PCR was less costly. Using MAS-PCR assay in MDR-TB detection allowed us to obtain results in 4 hours (amplification and electrophoresis), compared with automated culture methods or microscopic observation drug susceptibility assay which required 7-15 days each (B.R. IMPERIALE & al. [21] ; L. SOLARI & al. [23] ). Also, MAS-PCR saved approximately 28-41 days in MDR-TB diagnosis compared with DST on Löwenstein-Jensen medium, the gold standard assay (B.R. IMPERIALE & al. [21] ).
Conclusion
MAS-PCR proved to be a low-cost and time-saving technique, with good sensitivity and specificity for detection of mutations that induce resistance to RIF and INH that can be used in the management of MDR-TB cases. 
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